AR-301 in S. aureus Ventilator-Associated Pneumonia

Phase 3, randomised, double-blind trial in ventilator-associated pneumonia (VAP) comparing AR-301 + SOC with Placebo + SOC (2 arms). Primary endpoints: Clinical Cure Rates of standard of care (SOC) alone and SOC with AR-301 at 21 days, Safety of AR-301 by treatment-emergent adverse events at 21 days and 1 more. Started May 2019; status: completed.